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Summary
 
Transgenic mice carrying a 380-kb region of the human immunoglobulin (Ig) 
 
l
 
 light (L) chain
locus in germline configuration were created. The introduced translocus on a yeast artificial
chromosome (YAC) accommodates the most proximal Ig
 
l
 
 variable region (V) gene cluster, in-
cluding 15 V
 
l
 
 genes that contribute to 
 
.
 
60% of 
 
l
 
 L chains in humans, all J
 
l
 
-C
 
l
 
 segments,
and the 3
 
9
 
 enhancer. HuIg
 
l
 
YAC mice were bred with animals in which mouse Ig
 
k
 
 produc-
 
tion was silenced by gene targeting. In the 
 
k
 
2/2
 
 background, human Ig
 
l
 
 was expressed by
 
z
 
84% of splenic B cells. A striking result was that human Ig
 
l
 
 was also produced at high levels
in mice with normal 
 
k
 
 locus. Analysis of bone marrow cells showed that human Ig
 
l
 
 and mouse
Ig
 
k
 
 were expressed at similar levels throughout B cell development, suggesting that the Ig
 
l
 
translocus and the endogenous 
 
k
 
 locus rearrange independently and with equal efficiency at the
same developmental stage. This is further supported by the finding that in hybridomas express-
ing human Ig
 
l
 
 the endogenous L chain loci were in germline configuration. The presence of
somatic hypermutation in the human V
 
l
 
 genes indicated that the Ig
 
l
 
-expressing cells function
normally. The finding that human 
 
l
 
 genes can be utilized with similar efficiency in mice and
 
humans implies that L chain expression is critically dependent on the configuration of the locus.
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T
 
he light chain component of the Ig protein is encoded
 
by two separate loci, Ig
 
k
 
 and Ig
 
l
 
. The proportion of
antibodies containing 
 
k
 
 or 
 
l
 
 L chains varies considerably be-
tween different species (1–3); in mice the 
 
k
 
/
 
l
 
 ratio is 95:5,
compared with 60:40 in humans. Two models exist to ac-
count for the dominance of Ig
 
k
 
 expression in the mouse.
From the observations that murine Ig
 
l
 
-producing myelo-
mas have rearranged 
 
k
 
 L chain genes, whereas Ig
 
k
 
-produc-
ing cells have the 
 
l
 
 L chain locus in germline configura-
tion, it was proposed initially that 
 
k
 
 rearrangement must
occur before 
 
l
 
 rearrangement can begin (4, 5). Although
the same observation applies for human B cells, the propor-
tions of 
 
k
 
- and 
 
l
 
-producing cells are similar (4), suggesting
that other factors are involved. The second proposal is that
 
k
 
 and 
 
l
 
 loci are equally available for rearrangement at the
same time, but the mouse 
 
k
 
 locus is more efficient at en-
gaging the rearrangement process (for review see reference
6). The occasional finding of cells with rearranged 
 
l
 
 and the
 
k
 
 locus in germline configuration may support this (5, 7,
8). Any influence of antigen selection on the biased 
 
k
 
/
 
l
 
ratio is discounted by the finding that the ratio is similar in
fetal liver and in cells that have not encountered antigen
(9–13).
L chain V-J rearrangement occurs at the transition from
pre-B-II to immature B cells, where the surrogate L chain
associated with membrane Ig
 
m
 
 is replaced by 
 
k
 
 or 
 
l
 
 (14).
Although the timing of L chain rearrangement is essentially
defined, the processes that activate L chain locus rearrange-
ment are not fully understood. From locus-silencing exper-
iments, it is apparent that 
 
k
 
 rearrangement is not a prereq-
uisite for 
 
l
 
 recombination (15), but instead that 
 
k
 
 and 
 
l
 
rearrangements are independent events (16), the activation
of which may be affected by differences in the strength of
the respective enhancers. Targeted deletion of the 
 
k
 
 3
 
9
 
 en-
hancer in transgenic mice showed that this region is not es-
sential for 
 
k
 
 locus rearrangement or expression but is re-
quired for establishing the 
 
k
 
/
 
l
 
 ratio (17). A region that
may regulate the accessibility of the human 
 
l
 
 locus has
been identified 
 
z
 
10 kb downstream of C
 
l
 
7 (18, 19).
Functional analysis using reporter gene assays identified a
core enhancer region flanked by elements that can drasti-
cally reduce enhancer activity in pre-B cells (18). Although
transfection studies showed that the 
 
k
 
 and 
 
l
 
 3
 
9
 
 enhancer
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regions appear to be functionally equivalent, the core en-
hancer motifs are flanked by functional sequences that are
remarkably dissimilar. The human Ig
 
l
 
 locus on chromo-
 
some 22q11.2 is 1.1 Mb in size and typically contains 70 V
 
l
 
genes and 7 J
 
l
 
-C
 
l
 
 gene segments (20, 21). Approximately
half of the V
 
l
 
 genes and J
 
l
 
-C
 
l
 
1, 2, 3, and 7 are regarded
as functional. The V
 
l
 
 genes are organized in three clusters,
with the members of a particular V gene family contained
within the same cluster. There are 10 V
 
l
 
 gene families,
with the largest, V
 
l
 
III, having 23 members. In human pe-
ripheral blood lymphocytes, V gene segments of families I,
II, and III from the J-C proximal cluster A are preferen-
tially rearranged, with the contribution of the 2a2 V
 
l
 
 seg-
ment (2–14 using a position-based nomenclature; reference
22) being unusually high (23). All 
 
l
 
 gene segments have
the same polarity that allows deletional rearrangement (24).
The diversity of the Ig
 
l
 
 repertoire is provided mainly by
V
 
l
 
-J
 
l
 
 combination. Additional CDR3 diversity due to N
 
(nonencoded)
 
1
 
 or
 
 P 
 
(palindromic) nucleotide additions at
the V to J junction is present in human sequences, although
not as extensively as in IgH rearrangement, but is absent in
sequences from mice (25–28), where the TdT (terminal
deoxyribonucleotide transferase) activity is downregulated
at the time of L chain rearrangement.
Here we have introduced a 410-kb yeast artificial chro-
mosome (YAC), which contains most of the V
 
l
 
 genes of
cluster A and all the J
 
l
 
-C
 
l
 
 segments in germline configu-
ration, into mice that have one or both endogenous Ig
 
k
 
 al-
leles disrupted. The translocus shows high expression in
both backgrounds, and is able to compete equally with the
endogenous mouse 
 
k
 
 locus.
 
Materials and Methods
 
The HuIg
 
l
 
YAC, Introduction into Embryonic Stem Cells, and Der-
ivation of Transgenic Mice.
 
The 410-kb HuIg
 
l
 
YAC, accommo-
dating a 380-kb region (V
 
l
 
-JC
 
l
 
) of the human 
 
l
 
 L chain locus
 
with V, J, and C genes in germline configuration, was constructed
 
as previously described (29). To allow selection, two copies of the
 
neomycin resistance gene (
 
NEO
 
r
 
) were site-specifically integrated
into the ampicillin gene on the left (centromeric) YAC arm. YAC-
containing yeast cells were fused with HM-1 embryonic stem (ES)
cells (a gift from D. Melton, Department of Pathology, University
Medical School, Edinburgh, UK), as previously described (30), and
G418-resistant colonies were picked and analyzed 2–3 wk after
 
protoplast fusion. ES cells containing a complete HuIg
 
l
 
YAC copy,
confirmed by Southern hybridization, were used for blastocyst in-
jection to produce chimeric animals (31). Breeding of chimeric an-
imals with BALB/c mice resulted in germline transmission. Further
 
breeding with 
 
k
 
2/2
 
 mice (32) established the lines for analysis.
 
Southern Blot Analysis.
 
Conventional DNA was obtained (33)
or high molecular weight DNA was prepared in agarose blocks
(34). For the preparation of testis DNA, tissues were homo-
genized and passed through 70 
 
m
 
M nylon mesh. Pulsed-field gel
electrophoresis (PFGE) conditions to separate in the 50–900 kb
range were 1% agarose, 180 V, 70 s switch time, and 30 h run-
ning time at 3.5
 
8
 
C. Hybridization probes were Cl213 and the
left YAC arm probe (LA) comprising LYS2 (29).
Hybridoma Production and ELISA Assay. Hybridomas were ob-
tained from 3-mo-old HuIglYAC/k1/2 animals by fusion of
splenocytes with NS0 myeloma cells (35). After fusion, cells were
plated on 96-well plates such as to obtain single clones. Human
and mouse antibody production was determined in sandwich
ELISA assays (36) on MaxiSorp plates (Nalge Nunc, Denmark).
For the detection of human or mouse Igl, coating reagents were
a 1:500 dilution of anti–human l L chain mAb HP-6054 (L 6522;
Sigma Chemical Co.) or a 1:500 dilution of the 2.3 mg/ml rat
anti–mouse l mAB (L 2280; Sigma Chemical Co.), respectively.
Respective binding was detected with biotinylated antibodies:
polyclonal anti–human l (B 0900; Sigma Chemical Co.), a 1:1,000
dilution of polyclonal anti–mouse l (RPN 1178; Amersham In-
ternational) or rat anti–mouse Igl (No. 021172D; PharMingen)
followed by streptavidin-conjugated horseradish peroxidase (Am-
ersham International). Mouse IgG2al myeloma protein from
HOPC1 (M 6034; Sigma Chemical Co.) and human serum IgGl
(I 4014; Sigma Chemical Co.) were used to standardize the assays.
To determine mouse k L chain levels, plates were coated with a
1:1,000 dilution of rat anti–mouse k, clone EM34.1 (K 2132;
Sigma Chemical Co.), and bound Ig was detected using biotiny-
lated rat mAb anti–mouse Igk (Cat. No. 04-6640; Zymed).
Mouse myeloma proteins IgG2ak and IgG1k (UPC10, M 9144,
and MOPC21, M 9269; Sigma Chemical Co.) were used as stan-
dards. For detection of mouse IgM, plates were coated with poly-
clonal anti–mouse m (The Binding Site, UK) and bound Ig was
detected with biotinylated goat anti–mouse m (RPN1176; Amer-
sham International) followed by streptavidin-conjugated horserad-
ish peroxidase. Mouse plasmacytoma TEPC183, IgMk (M 3795;
Sigma Chemical Co.) was used as a standard.
Flow Cytometry Analysis. Cell suspensions were obtained
from bone marrow, spleen, and Peyer’s patches (PPs). Multicolor
staining was then carried out with the following reagents in com-
binations (illustrated in Fig. 4): FITC-conjugated anti–human l
(F 5266; Sigma Chemical Co.), PE-conjugated anti–mouse c-kit
(CD117) receptor (clone ACK45, cat. No. 09995B; PharMin-
gen), PE-conjugated anti–mouse CD25 (IL-2 receptor) (clone
3C7, P 3317; Sigma Chemical Co.), biotin-conjugated anti–
human  k (clone G20-193, cat. No. 08172D, PharMingen), biotin-
conjugated anti-mouse CD19 (clone 1D3, cat. No. 09654D;
PharMingen), followed by Streptavidin-Quantum red (S 2899;
Sigma Chemical Co.) or Streptavidin-PerCP (cat. No. 340130;
Becton Dickinson) and rat monoclonal anti–mouse k L chain (clone
MRC-OX-20, cat. MCA152; Serotec, UK) coupled according
to the manufacturer’s recommendations with allophycocyanin
(APC) (PJ25C; ProZyme). Data were collected from 106 stained
cells on a FACScalibur® flow cytometer (Becton Dickinson) as
previously described (32). Cells were first gated on forward and
side scatter to exclude dead cells. To obtain accurate percentage
distribution for comparison, cells from normal mice were stained
in parallel. In addition, human peripheral blood lymphocytes
were purified on Ficoll gradients (1.077 g/ml) and stained with
PE-conjugated anti–human CD19 antibody (P 7437, clone SJ25-C1;
Sigma Chemical Co.), biotinylated anti–human k followed by
Streptavidin-Quantum red, and FITC-conjugated anti–human l
antibodies as above.
For reverse transcriptase (RT)-PCR cloning of Vl genes, PP cells
were stained with FITC-conjugated peanut agglutinin (PNA)
1Abbreviations used in this paper: ES, embryonic stem; Hu, human; N, non-
encoded; P, palindromic; PFGE, pulsed-field gel electrophoresis; PNA,
peanut agglutinin; PP, Peyer’s patch; RACE, rapid amplification of
cDNA ends; RSS, recombination signal sequence(s); RT, reverse tran-
scriptase; TdT, terminal deoxyribonucleotide transferase; YAC, yeast arti-
ficial chromosome.1613 Popov et al.
(L 7381; Sigma Chemical Co.) and PE-conjugated anti–mouse
B220 antibodies (P 3567; Sigma Chemical Co.). Double-positive
cells were sorted on the FACStarPlus flow cytometer (Becton
Dickinson) as previously described (32) and 5 3 103 cells were
lysed in denaturing solution (37). 59RACE was carried out as de-
scribed below with one modification: 2 mg of carrier RNA was
added to the cell lysates before RNA extraction and precipitation.
Cloning and Sequencing of 59RACE Products. Spleen RNA was
prepared as previously described (37) and for cDNA preparation
2–3 mg of RNA was ethanol precipitated and air dried. For rapid
amplification of 59 cDNA ends (59RACE) (38) first strand cDNA
was primed with oligo(dT)22, and 100 U of Super Script II re-
verse transcriptase (GIBCO BRL) was used at 468C according to
the manufacturer’s instructions with 20 U of placental RNAse
inhibitor (Promega). The DNA/RNA duplex was passed through
1 ml G-50 equilibrated with TE (10 mM Tris-HCl, pH 7.8, and
1 mM EDTA) in a hypodermic syringe to remove excess oligo(dT).
For G-tailing, 20 U of TdT (Cambio, UK) was used according to
standard protocols (39). Double-stranded cDNA was obtained
from G-tailed single-stranded cDNA by addition of oligonucle-
otide Pr1 (see below), 100 mM dNTP, and 2.5 U of Klenow
fragment (Cambio), followed by incubation for 10 min at 408C.
After heating the reaction for 1 min at 948C and extraction
with phenol-chloroform, the double-stranded cDNA was passed
through G-50 to remove primer Pr1. PCR amplifications, 35 cy-
cles, were carried out in the RoboCycler Gradient 96 Thermal
Cycler (Stratagene) using oligonucleotides Pr2 and Pr3. For PCR
of PP cDNA 50 cycles were used: 40 cycles in the first amplifica-
tion and 10 cycles in additional amplifications. Pfu Thermostable
Polymerase (Stratagene) was used instead of Taq polymerase to
reduce PCR error rates. The amplification products were puri-
fied using a GENECLEAN II kit (BIO 101) and reamplified for
five cycles with primers Pr2 and Pr4 to allow cloning into EcoRI
sites. Oligonucleotide for 59RACE of Vl genes were: Pr1,
59-AATTCTAAAACTACAAACTGCCCCCCCCA/T/G-39;
Pr2, 59-AATTCTAAAACTACAAACTGC-39 (sense); Pr3,
59-CTCCCGGGTAGAAGTCAC-39 (reverse); and Pr4, 5’-AAT-
TCGTGTGGCCTTGTTGGCT-39 (reverse nested).
Vl PCR products of z500 bp were cut out from agarose gels
and purified on GENECLEAN II. The DNA was incubated in
50 mM Tris-HCl, pH 7.4, and 10 mM MgCl2, with 100 mM
dGTP/dCTP and 1 U of Klenow fragment for 10 min at room
temperature. Under these conditions the Klenow fragment re-
moved the 39 ends of the PCR products (AATT) leaving ligat-
able EcoRI overhangs. DNA was ligated with EcoRI-restricted
pUC19, transformed into competent E. coli XL1Blue, and colo-
nies were selected on X-Gal/IPTG/amp plates. Plasmid DNA
prepared from white colonies was used for sequencing. Sequenc-
ing of both strands was done on the ABI 373 automated se-
quencer (Applied Biosystems, Inc.) in the Babraham Institute
Microchemical Facility.
Results
The Transgenic Human Igl Locus. The human Igl trans-
locus (Fig. 1) was assembled as a YAC by recombining one
YAC containing about half of the human Vl gene seg-
ments with three overlapping cosmids containing Vl and
Jl-Cl gene segments and the 39 enhancer (29). This pro-
duced a 410-kb YAC accommodating a 380-kb region of
the human l L chain locus containing 15 Vl genes re-
garded as functional, 3 Vls with open reading frames not
found to be expressed, and 13 Vl pseudogenes (40). This
HuIglYAC was introduced into ES cells by protoplast fu-
sion (30) and chimeric mice were produced by blastocyst
injection (31). The ES cell clone used for blastocyst injec-
tion showed a 450-kb NotI fragment corresponding to
HuIglYAC, as identified by PFGE and Southern hybrid-
ization with probes to the 39 end of the construct, identify-
ing the Cl213 regions, and to the left centromeric YAC
arm at the 59 end, identifying the LYS2 gene (data not
shown). Germline transmission was obtained, and PFGE
analysis of testis DNA from one animal is illustrated in Fig.
2. A NotI fragment larger than 380 kb is necessary to ac-
commodate this region of the HuIglYAC, and the 450-kb
band obtained indicates random integration involving the
single NotI site 39 of Jl-Cl and a NotI site in the mouse
chromosome. Digests with EcoRI/HindIII and hybridiza-
tion with the Cl213 probe further confirmed the integrity
of the transferred HuIglYAC (Fig. 2). The results indi-
cated that one complete copy of the HuIglYAC was inte-
grated in the mouse genome.
Human Igl Expression Is Dominant in Mouse k2/2 Ani-
mals. To assess the human l L chain repertoire for the pro-
duction of authentic human antibodies, the HuIglYAC
mice were bred with mice in which endogenous Igk pro-
duction was silenced by gene targeting (32). In these k2/2
mice, the mouse Igl titers are elevated compared with k1/1
strains (32, 41). Serum titrations (Fig. 3) showed that human
Igl antibody titers in HuIglYAC/k2/2 mice are between 1
and 2 mg/ml, which is up to 10-fold higher than average
mouse Igl levels. Interestingly, in the HuIglYAC/k2/2
mice, the mouse Igl production returned to levels similar to
that found in normal mice. High numbers of human Igl1
Figure 1. The HuIglYAC accommodates a
380-kb region of the human l L chain locus in au-
thentic configuration with all Vl genes of cluster A
(21, 22, 40), the Jl-Cl segments, and the 39 en-
hancer (17). Black boxes represent functional Vl
genes (3-27, 3-25, 2-23, 3-22, 3-21, 3-19, 2-18,
3-16, 2-14, 2-11, 3-10, 3-9, 2-8, 4-3, and 3-1) and
white boxes show Vl genes with open reading
frames (2-33, 3-32, and 3-12) that have not been
identified in productive rearrangements of human
lymphocytes (40). Pseudogenes are not shown. Black triangles (m) indicate V gene use in functionally Igl rearrangements (mutated [see Fig. 5] and un-
mutated) found by RT-PCR in spleen and sorted PP cells from HuIgl mice. Rearrangement to Jl1 was found in 5 sequences, Jl2 in 18, and Jl3 in 8.
The unique NotI restriction site is indicated. Probes to assess the integrity of the HuIglYAC, LA (left arm) and Cl213 are indicated.1614 Expression of a Human Igl Translocus in Mice
cells were also identified in flow cytometric analysis of
splenic B cells from HuIglYAC/k2/2 mice (Fig. 4 A), with
human l expressed on the surface of z84% of the B cells
and mouse Igl1 expressed on ,5% (data not shown).
Human Igl Expression Equals Mouse Igk Production. Assess-
ment of human Igl production in heterozygous HuIgl
YAC1/k1/2 mice allowed a detailed comparison of expres-
sion and activation of endogenous versus transgenic L chain
loci present at equal functional numbers. Serum analysis (Fig.
3) of mice capable of expressing both human l and mouse k
showed similar titers for human and mouse L chains. Human
Igl levels in HuIglYAC/k1/1 transgenic mice were simi-
lar to those in HuIglYAC/k1/2 mice. Total Ig levels in
HuIglYAC1/k1/2 mice were 1–2 mg/ml, with an average
contribution of z51% mouse Igk, 43% human Igl, and 6%
mouse Igl. As is also seen in human serum, the analysis of
individual HuIglYAC/k1/2 animals showed there were
variations in the l/k ratios. Three of the HuIglYAC/k1/2
mice produced somewhat higher k levels, whereas in two
mice the human l levels were higher than the Igk titers. In
HuIglYAC/k1/2 mice, high translocus expression was also
found in B2201 B cells from different tissues, with 38% of
spleen cells expressing human l and 45% expressing mouse
k (Fig. 4 A). As illustrated, these values closely resemble the
levels in human volunteers with 34% Igl1 versus 51% Igk1
in CD191 peripheral blood lymphocytes. In HuIglYAC/
k1/1 mice, which carry a wild-type k locus, the levels of Igl
Figure 2. Southern blot anal-
ysis of HuIglYAC integration.
(Left) NotI-digested testis DNA
resolved on PFGE and hybrid-
ized with the Cl213 probe.
The same size band was obtained
with the left arm probe (data not
shown). The majority of the hy-
bridization signal remains in the
compression band (CB) presum-
ably due to protection of the
NotI site by methylation.
(Right) EcoRI/HindIII digests
hybridized with the Cl213
probe. Lane 1, HuIglYAC ES
cell DNA from a protoplast fusion clone; lane 2, normal ES cell DNA;
lane 3, human genomic DNA (XZ); lane 4, human KB carcinoma (53)
DNA; lanes 5 and 6, tail DNA from two HuIglYAC germline transmis-
sion mice. Note that the human DNA shows an additional 5.2-kb band
that represents an allelic variation (54).
Figure 3. Human Igl, mouse Igk, and mouse Igl serum titers for
HuIglYAC/Mok1/2 and HuIglYAC/Mok2/2 mice (five to six mice per
group kept in germfree conditions and five human sera). Antibody levels
presented were obtained from 2–3-mo-old animals but the serum titers from
older mice were similar. From the five HuIglYAC/Mok1/2 mice tested,
three animals had somewhat higher mouse Igk titers than human Igl,
whereas two animals showed higher human Igl levels. The controls show
L chain distribution in human and normal mouse serum. Total Ig levels are
in good agreement with the sum of individual titers (data not shown).
Figure 4. Flow cytometric analysis of L chain expression during B cell
development. (A) Distribution of k and l L chain expression of CD191
human peripheral lymphocytes and B2201 mouse spleen cells from HuIgl
YAC/Mok1/2, HuIglYAC/Mok1/2, and HuIglYAC/Mok2/2 mice. (B)
Mouse Igk and human Igl L chain expression in CD191/c-kit1 (top) and
CD191/CD251 (bottom) HuIglYAC/Mok1/2 bone marrow cells.1615 Popov et al.
are z25% and endogenous k levels are z60% (Fig. 4 A). It is
likely that these differences in expression levels are depen-
dent on the number of active gene loci.
To assess the developmental stage at which the high con-
tribution of the human l translocus becomes established, we
examined surface L chain expression by bone marrow cells
of HuIglYAC/k1/2 mice. For this, B cell lineage marker
CD19 and specific antibodies to human l and mouse k were
used in four-color staining with the early B cell markers c-kit
(CD117) and CD25. Fig. 4 B shows that surface L chain ex-
pression (human l or mouse k) was detectable on a similar
small proportion of B cells at each of these stages of devel-
opment, which suggests that human and mouse L chain re-
arrangements are simultaneous. The specificity of the staining
detecting mouse k and human l on small numbers of early
B cells, which has been reported independently (42), was ver-
ified by the absence of similar positive cells in the analysis of
bone marrow from control mice (data not shown).
DNA Rearrangement and Diversification of a Highly Active
Human l Translocus. To further clarify the potential of
the L chain translocus to contribute to the antibody reper-
toire, we analyzed human l and mouse k L chain produc-
tion using individual hybridoma clones from HuIglYAC/
k1/2 mice. Results from two fusions suggest that human l
and mouse k L chain–producing cells were present in the
spleen of HuIglYAC/k2/1 mice at similar frequencies.
Furthermore, in the hybridomas the amounts of human Igl
(2–20 mg/ml) or mouse Igk (4–25 mg/ml) were very simi-
lar. To determine whether Igk rearrangement precedes
Igl, as found in mice and humans (4, 5), the configuration
of the endogenous Igk and the human l translocus were
analyzed in these hybridomas. Southern blot hybridization
of randomly picked hybridoma clones showed that in 11
human Igl expressers, 7 had the mouse k locus in germline
configuration, 1 clone had mouse Igk rearranged, and 3
clones had the mouse k locus deleted, whereas in 19 mouse
Igk expressers, all but 2 had the human Igl locus in germ-
line configuration. This result suggests that there is no locus
activation bias and further emphasizes that the human l
translocus performs with similar efficiency as the endog-
enous k locus.
The capacity of the human l locus to produce a diverse
antibody repertoire is further documented by the V-J rear-
rangement. Sequences were isolated from spleen and PP
cells by 59RACE PCR amplification to avoid bias from
specific V gene primers. The use of individual Vl genes is
indicated by the triangles in Fig. 1, and shows that a sub-
stantial proportion of the Vl genes on the translocus are
being used in productive rearrangements, with Vl3-1 and
Vl3-10 being most frequently expressed. In Vl-Jl rear-
rangements, Jl2 was used preferentially and Jl3 and 1 were
used less frequently, whereas, as expected, Jl4, 5, and 6
were not used as they are adjacent to cCs. Extensive vari-
ability due to N or P sequence additions, which is found
in human but not mouse L chain sequences (25, 27, 28),
was not observed. Sequences obtained by RT-PCR from
FACS®-sorted PP germinal center B cells (B2201/PNA1)
revealed that somatic hypermutation is operative in HuIgl
YAC mice (Fig. 5). We identified 11 unique Vl-Jl rear-
rangements with two or more changes in the V region, ex-
Figure 5. Hypermutated human Vl sequences from sorted B2201 and PNA1 PP B cells from HuIgl1YAC/k1/2 mice. The sequences are a represen-
tative selection of the functional Vl-Jl rearrangements (indicated by the triangles in Fig. 1) isolated from RT-PCR.1616 Expression of a Human Igl Translocus in Mice
cluding the CDR3, which may be affected by Vl-Jl re-
combination. The majority of mutations lead to amino acid
replacements, but there was no preferential distribution in
CDR1 and CDR2.
Discussion
The ratio of l to k L chain expression varies consider-
ably between different species (1–3, 43, 44), and in mice
the low l L chain levels are believed to be a result of ineffi-
cient activation of the mouse l locus during B cell differ-
entiation (for review see reference 6). The Igl (z40%) to
Igk (z60%) ratio in humans is more balanced and suggests
that both l and k play an equally important role in im-
mune responses. This is supported by the finding that the
mouse Vl genes are most similar to the less frequently used
distal human Vl gene families, whereas no genes compara-
ble to the major contributors to the human Vl repertoire
are present in the mouse locus (40). With the HuIglYAC,
these Vl genes are available, and are able to make a signifi-
cant contribution to the antibody repertoire. The 410-kb
HuIglYAC translocus accommodates V gene region clus-
ter A containing at least 15 functional Vl genes (see Fig. 1).
In humans, cluster A is the main contributor to the l anti-
body repertoire, with Vl 2-14 (2a2) expressed most fre-
quently at 27% in blood lymphocytes (23). We also find
expression of Vl 2-14 in the translocus mice, but the main
contributors to the l L chain repertoire were 3-1 (the Vl
gene most proximal to the J-C region) and 3-10, both of
which are expressed at z3% in humans. Although the va-
lidity of conclusions about the contribution of different
genes is dependent on the numbers examined, the overex-
pression of Vl3-1 (11 sequences) and Vl3-10 (8 se-
quences) in the 31 sequences obtained may imply that rear-
rangement or selection preferences are different in mice
and humans. Analysis of recombination signal sequences
(RSS) in mouse L chains showed that k and l RSS differ
significantly, and that those genes with the highest similar-
ity to consensus RSS rearrange most frequently (45). The
RSS of Vl3-1 and Vl3-10 show a 100% match with the
mouse consensus sequence, which may explain their fre-
quent expression in the translocus mice. In addition, most
human Vl RSS match the established consensus sequence
significantly better than mouse Vls (21, 45).
We found extensive somatic hypermutation of many re-
arranged human Igl sequences, indicating that they are
able to participate in normal immune responses. The levels
of mutation in B2201/PNA1 PP cells from HuIglYAC
translocus mice were similar to what has been reported for
mouse L chains (46). Rather unexpected was the pattern of
somatic hypermutation with similar numbers of silent and
replacement point mutations found in the complementar-
ity-determining and framework regions. Somatic hyper-
mutation is usually associated with a higher level of re-
placement mutations in CDRs and more silent mutations
in the framework regions, and the distribution observed
here may argue against efficient antigen selection having
taken place. Interestingly, however, l L chain sequences
obtained from human peripheral blood lymphocytes also
showed high numbers of mutations in framework 2 (23).
Part of framework 2 lies at the interface of the VL and VH
domains and it has been suggested that this region may be
important for optimal H and l L chain interaction and, in
particular, interaction of the human l L chain and the en-
dogenous mouse H chain (26).
In the mouse, unlike in humans, L chain diversification
due to untemplated nucleotide addition is essentially ab-
sent, because TdT expression has been downregulated by
the stage at which L chain rearrangement takes place (28,
47). This concept is challenged by the observation that
mouse L chain rearrangement can occur at the same time as
VH to DJH rearrangements (48) or even earlier (42). Our re-
sults also show L chain rearrangement at the pre-B cell stage
with a similar number of human l- or mouse k-expressing
B cells also expressing c-kit1 or CD251 (see Fig. 4). Al-
though the cell numbers are small, the results suggest that
there is no preferential activation of either the human l
translocus or the endogenous k locus. However, despite
this early activation, there is no accumulation of N or P
nucleotide diversity in the rearranged human l L chains,
unlike rearranged l L chains from human peripheral B cells
(27). The small number (,1%) of human Igl1/mouse
Igk1 double positive spleen and bone marrow cells may in-
dicate that haplotype exclusion at the L chain level is less
strictly controlled than is IgH exclusion (49).
In transgenic mice carrying Ig regions in germline con-
figuration on minigene constructs, efficient DNA rear-
rangement and high antibody expression levels are rarely
achieved. Competition with the endogenous locus can be
eliminated using Ig knockout strains, in which transgene
expression is usually improved (50). Poor transloci expres-
sion levels could be a result of the failure of human se-
quences to work efficiently in the mouse background or,
alternatively, of the absence of locus-specific control re-
gions that are more likely to be included on larger trans-
genic regions (51–53). Recently we addressed this question
in transgenic mice by the introduction of different sized
minigene- and YAC-based human k L chain loci (53). The
result showed that neither the size of the V gene cluster nor
the V gene numbers present were relevant to achieving
high translocus expression levels. The YAC-based loci
contained downstream regions of the human k locus, and it
is possible that the presence of an undefined region with
cis-controlled regulatory sequences may have been crucial
in determining expressibility and subsequently L chain choice.
The HuIglYAC contains equivalent regions from the hu-
man Igl locus, which may promote the use of the translocus
in the L chain repertoire. Hybridomas from HuIglYAC1/
k1/2 mice show no evidence for a bias in L chain locus se-
lection during development, as demonstrated by the absence
of rearrangement of the nonexpressed locus. This is in con-
trast with what is seen in Ig expressing mouse and human
B cell clones (4, 5), and supports the model that l and k re-
arrangements are indeed independent (15, 54) and that
poor Igl expression levels in mice may be the result of in-
efficient signals acting during recombination (16). A possi-1617 Popov et al.
ble signal that initiates L chain recombination has been
identified through gene targeting experiments where the 39
k enhancer was deleted (17). In these mice, the k/l ratio
was reduced from 20:1 in normal mice down to 1:1, and the
k locus was largely in germline configuration in l-expressing
cells, as we also see in the HuIglYAC1/k1/2 hybridoma
clones. The high level of human Igl expression in the
HuIglYAC1/k1/2 mice could be due to the strength of
the downstream enhancer of the human l locus. An analy-
sis of human L chain enhancer activities identified three
synergistic modules at the 39 end of the l locus which con-
stitute a powerful pre-B cell specific enhancer that appears
to be stronger than the corresponding k enhancer (55).
Analysis of the mouse l 39 enhancer suggests the biased k/l
ratio in mice may be a direct result of the differences in lo-
cus specific regulation provided by the respective enhancers
(19, 56). The results suggest that strength and ability of the
human 39 l enhancer to function in the mouse background
may be the reason that l and k loci can compete equally at
the pre-B cell stage to initiate L chain rearrangement, re-
sulting in the similar levels of human Igl and mouse Igk
seen in the HuIglYAC1/k1/2 mice.
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